Risk Factors Update Summary
- May not realize expected benefits under GSK License Agreement, impacting revenue and operating results.
- Net loss decreased from $62 million in 2022 to $67 million in 2023.
- Full-time employees decreased from 36 to 29 as of March 1, 2024.
- Accumulated deficit decreased from approximately $422 million to $355 million.
- Product liability coverage increased from $10 million per occurrence to $25 million per occurrence.
- Cash, cash equivalents, and investments increased from $73 million to $98 million in 2023.
- Product liability coverage increased from $10 million in the aggregate per year to $25 million in the aggregate per year.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1178253&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.